CABIO(SH:688089) Bei Ke Cai Jing·2025-09-04 04:48Group 1 - The core point of the article is that the company Jia Biyou has decided to terminate the acquisition of a stake in Ouyi Biological due to changes in market conditions and the operational status of the target company, which was a shift from the initial planning stage [1] - Jia Biyou had been planning the acquisition since last year, with two adjustments to the transaction plan and inquiries from the Shanghai Stock Exchange [1] - The latest plan indicated that Jia Biyou intended to acquire 63.2134% of Ouyi Biological for approximately 831 million yuan, with a premium rate of 441.23% [1] Group 2 - Following the announcement of the termination, Jia Biyou's stock price experienced a continuous decline from September 1 to September 3, raising concerns among investors about potential losses [2] - In response to investor concerns, Jia Biyou stated that the decision to terminate the acquisition was made after careful consideration and was aimed at protecting the interests of the company and its investors [2] - The company emphasized its commitment to maintaining strategic focus, advancing technological innovation, and exploring further cooperation opportunities with Ouyi Biological in the future [2]